SNRPD3 Antibody

What is the biological function of SNRPD3 in RNA processing?

SNRPD3 plays a critical role in pre-mRNA splicing as a core component of the spliceosomal U1, U2, U4, and U5 small nuclear ribonucleoproteins (snRNPs), which are the building blocks of the spliceosome. It functions in both the pre-catalytic spliceosome B complex and activated spliceosome C complexes. As part of the minor spliceosome, SNRPD3 participates in splicing U12-type introns in pre-mRNAs. Additionally, as a component of the U7 snRNP, it contributes to histone pre-mRNA 3'-end processing .

Why do researchers observe a discrepancy between calculated and observed molecular weights of SNRPD3?

While the calculated molecular weight of SNRPD3 is 18 kDa, it is frequently observed at approximately 14 kDa in Western blot analyses . This discrepancy may be attributed to:

• Post-translational modifications affecting mobility

• Protein folding characteristics

• The high charge density of the protein affecting SDS-binding

• Potential proteolytic processing during sample preparation

Researchers should always include appropriate controls when first working with SNRPD3 antibodies to establish the correct band pattern for their experimental system.

What applications are validated for SNRPD3 antibodies?

SNRPD3 antibodies have been validated for multiple applications including:

• Western Blot (WB): Typically at 1:200-1:1000 dilution

• Immunohistochemistry (IHC): Typically at 1:20-1:200 dilution

• Immunofluorescence (IF): Optimal at 0.25-2 μg/mL

• Immunoprecipitation (IP): Successfully used in protein complex studies

• ELISA: Validated in multiple antibody preparations

How can researchers optimize SNRPD3 immunoprecipitation for protein-protein interaction studies?

For effective SNRPD3 immunoprecipitation:

• Lysate preparation:

  • Use EBC buffer (50 mM Tris pH 7.3, 150 mM NaCl, 0.5% NP-40, 1 mM MgCl₂, with protease inhibitors)

  • Sonicate samples 6 times for 10 seconds

  • Add benzonase (500 U) and incubate for 1 hour at 4°C under rotation

• Immunoprecipitation conditions:

  • Adjust NaCl to final concentration of 150 mM

  • Use protein A/G beads pre-loaded with SNRPD3 antibody (4-5 μg)

  • Incubate for 2 hours at 4°C under rotation

  • Wash 4-5 times with IP buffer

• Detection of protein complexes:

  • For MYCN-SNRPD3-PRMT5 complex detection, use sequential or dual IP strategies

  • Consider crosslinking approaches for transient interactions

What controls are essential when assessing SNRPD3 function through knockdown experiments?

Based on published methodologies, critical controls include:

The choice of control cell lines is particularly important; MYCN-amplified lines (SK-N-BE(2)-C, KELLY) show strong SNRPD3 dependency, while others (SK-N-FI) show minimal effects .

How does SNRPD3 methylation status affect antibody recognition and experimental results?

SNRPD3 is methylated by PRMT5 at arginine/glycine-rich "RG motifs" in the region carboxyl-terminal to its Sm domains. This methylation affects:

• Antibody recognition: Some antibodies may have differential recognition of methylated vs. unmethylated SNRPD3

• Complex formation: Methylation is required for Sm ring assembly with SNRPB and SNRPD1

• Experimental manipulation: PRMT5 inhibitors (such as JNJ-64619178) reduce SNRPD3 methylation and can be used as experimental tools

• Cross-reactivity concerns: Antibodies raised against methylated epitopes may show variable reactivity depending on cellular context

Researchers should validate their antibody's sensitivity to SNRPD3 methylation status, particularly when studying the MYCN-SNRPD3-PRMT5 axis in neuroblastoma models .

How can SNRPD3 antibodies be used to study alternative splicing patterns in cancer?

SNRPD3 antibodies can be employed to investigate alternative splicing through several approaches:

• RNA immunoprecipitation followed by sequencing (RIP-seq):

  • Use SNRPD3 antibodies to pull down RNA-protein complexes

  • Sequence associated RNAs to identify SNRPD3-bound transcripts

  • Analyze for enrichment of specific splicing patterns

• Chromatin immunoprecipitation (ChIP) for co-transcriptional splicing:

  • SNRPD3 can be detected at specific genomic loci during co-transcriptional splicing

  • Correlate with MYCN binding sites in neuroblastoma models

• Proximity-based labeling approaches:

  • CRISPR-based RNA proximity proteomics (CBRPP) can identify proteins associated with SNRPD3-regulated transcripts

  • Based on dCas13 fusion with proximity labeling enzymes

• Differential splicing analysis after SNRPD3 manipulation:

  • RNA-seq analysis using tools like leafcutter or rMATS

  • Focus on exon skipping events, which predominate upon SNRPD3 manipulation

What is the evidence linking SNRPD3 to neuroblastoma progression, and how can antibodies help investigate this connection?

SNRPD3 has been strongly implicated in neuroblastoma progression through multiple lines of evidence:

• Expression correlation with outcome:

  • High SNRPD3 expression significantly correlates with poor patient outcome in neuroblastoma

  • Multivariate Cox regression analysis shows SNRPD3 expression is an independent prognostic factor

  • Patients with Stage 4 disease, age >18 months at diagnosis, or MYCN amplification show significantly higher SNRPD3 expression

• Mechanistic relationship with MYCN:

  • MYCN directly binds the SNRPD3 promoter (confirmed by ChIP-qPCR)

  • MYCN occupancy at the SNRPD3 promoter is 7-fold higher than control regions

  • SNRPD3 mRNA and protein expression decrease when MYCN is suppressed

• Functional impact:

  • SNRPD3 knockdown results in reduced cell viability and colony formation

  • In vivo xenograft experiments show SNRPD3 suppression can completely ablate tumor formation

  • SNRPD3 ensures fidelity of MYCN-driven alternative splicing

Antibody applications to further investigate this connection include tissue microarrays for patient stratification, co-IP studies of the MYCN-SNRPD3-PRMT5 complex, and ChIP-seq to map genome-wide SNRPD3 binding patterns .

How do experimental conditions affect SNRPD3 detection and what methodological solutions exist?

Several experimental conditions can significantly impact SNRPD3 detection:

How can researchers address potential cross-reactivity concerns with SNRPD3 antibodies?

SNRPD3 belongs to the small nuclear ribonucleoprotein core protein family, which includes closely related members. To address cross-reactivity:

• Validation strategies:

  • Perform siRNA/shRNA knockdown of SNRPD3 to confirm band specificity

  • Use multiple antibodies targeting different epitopes of SNRPD3

  • Include closely related family members (SNRPD1, SNRPD2) as controls

  • Perform mass spectrometry validation of immunoprecipitated proteins

• Enhanced specificity techniques:

  • For critical experiments, consider epitope-tagged SNRPD3 expression followed by tag-specific antibody detection

  • Perform peptide competition assays with the immunizing peptide

  • Use knockout/knockdown controls in parallel with all experiments

What are the key considerations when interpreting SNRPD3 expression data in different cancer types?

When analyzing SNRPD3 expression across cancer types, researchers should consider:

• Context-dependent function:

  • SNRPD3 dependency varies with MYCN/MYC status (strong in MYCN-amplified neuroblastoma and high-MYC cells)

  • Effects may be minimal in cells with low MYCN/MYC expression (e.g., SK-N-FI)

• Alternative splicing landscape:

  • SNRPD3 knockdown in MYCN-overexpressing cells increases differential splicing

  • Exon skipping is the predominant splicing event affected

  • Cell cycle regulators like BIRC5 and CDK10 are particularly affected

• Protein interactions:

  • MYCN-SNRPD3-PRMT5 complex formation is key in neuroblastoma

  • Different interactome may exist in other cancer types

  • Consider testing PRMT5 inhibitors (JNJ-64619178, GSK3326595) in SNRPD3-high cancers

• Prognostic value:

  • High expression correlates with poor outcomes in neuroblastoma

  • Similar patterns observed in other cancers including hepatocellular carcinoma

  • SNRPD3 is among the strongest independent prognostic factors among core spliceosome assembly genes

What methodological approaches can resolve discrepancies in SNRPD3 antibody results between different experimental systems?

When facing discrepancies between experimental systems:

• Standardize sample preparation:

  • For RNA analysis, use RNA Later or OCT compound with snap freezing

  • For protein analysis, use fresh rather than archived samples

  • Standardize cell lysis protocols (EBC buffer recommended)

• Antibody validation hierarchy:

  • Confirm antibody reactivity with recombinant SNRPD3

  • Verify knockdown/knockout effects on signal

  • Compare multiple antibodies against different epitopes

  • Test in multiple cell lines with variable SNRPD3 expression

• Application-specific optimization:

  • For IHC: Test both TE buffer pH 9.0 and citrate buffer pH 6.0 for antigen retrieval

  • For WB: Use gradient gels to resolve the 14-18 kDa region effectively

  • For IP: Optimize salt concentration (150 mM NaCl recommended)

  • For IF: Use methanol permeabilization after fixation

• Quantification standards:

  • Include recombinant protein standards for absolute quantification

  • Use SNRPD3-transfected and knockdown cells as positive and negative controls

How might SNRPD3 antibodies contribute to therapeutic development for MYCN-driven cancers?

SNRPD3 antibodies could facilitate therapeutic development through:

• Target validation studies:

  • Confirming SNRPD3 expression in patient samples

  • Correlating expression with treatment response

  • Identifying patient subgroups most likely to benefit from splicing-targeted therapies

• Drug screening applications:

  • Developing assays to measure SNRPD3 methylation status (by PRMT5)

  • Monitoring SNRPD3-MYCN complex formation in drug screens

  • Assessing effects of PRMT5 inhibitors on SNRPD3 function

• Companion diagnostic development:

  • SNRPD3 IHC could identify patients suitable for splicing-modulator therapy

  • Monitoring treatment response through SNRPD3-dependent splice variants

  • Combination therapy rational design based on SNRPD3 functional status

What novel methodological approaches could enhance SNRPD3 functional studies?

Emerging technologies that could advance SNRPD3 research include:

• Single-cell splicing analysis:

  • Combining single-cell RNA-seq with computational approaches to map SNRPD3-dependent splicing events at cellular resolution

  • Identifying rare cell populations with distinct SNRPD3 dependencies

• Live-cell imaging of splicing dynamics:

  • Using split fluorescent protein approaches to visualize SNRPD3-containing spliceosomes in real-time

  • Monitoring co-transcriptional splicing events involving SNRPD3

• CRISPR-based approaches:

  • Using CRISPR interference/activation to modulate SNRPD3 expression

  • Employing CRISPR-based RNA proximity proteomics (CBRPP) to identify proteins associated with SNRPD3-regulated transcripts

  • Creating conditional knockout models to study tissue-specific requirements for SNRPD3

• Structure-function analysis:

  • Developing antibodies against specific functional domains

  • Using proximity labeling approaches to map SNRPD3 interaction networks in different cellular contexts